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Abstract
Background: The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in
the absence of pre-existing autoimmunity is unknown.
Case presentation: We report the case of a melanoma patient treated for 8 months with pembrolizumab who
developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland
biopsy showed inflammatory changes suggestive of Sjögren’s syndrome, while brain MRI revealed enhancement of the
right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative
cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower
limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important
inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies
specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with
pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the
subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then
rituximab, which led to a quick clinical improvement.
Conclusions: Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe
neuro-Sjögren’s syndrome induced by pembrolizumab treatment.
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Background
Immune checkpoint inhibitors (CPIs) have transformed
the prognosis of several advanced malignancies, estab-
lishing new standards of care for both adjuvant and
metastatic settings. The use of CPIs is associated with a
large spectrum of immune side effects, known as
immune-related adverse events (irAEs), which may affect
every organ [1]. The immunological mechanisms beyond
irAEs have not been completely elucidated [1]. Pembro-
lizumab is a highly selective antiprogrammed cell death
1 (PD-1) humanized monoclonal antibody. The inci-
dence of connective tissue disease (CTD) induced by
CPIs treatment is unknown, while that of neurologic
irAEs has been reported to be approximately 2.9% [2, 3].
Almost 40 to 50% of these cases are associated with con-
comitant autoimmune response affecting other organs,
such as hepatitis, colitis and hypothyroidism. Frequently,
neurological irAEs arise within 6–12 weeks from the ini-
tiation of CPIs, although onset may be delayed and even
occur after the discontinuation of CPIs [2]. The related
neurologic toxicity spectrum involves a wide variety of
clinical presentations affecting both the central and per-
ipheral nervous systems, including myopathies, neuro-
muscular junction disorders, symmetrical length and
non-length-dependent peripheral neuropathies (includ-
ing axonal and demyelinating polyradiculoneuropathies),
asymmetric mononeuritis multiplex, cerebellar ataxia
and bilateral internuclear ophthalmoplegia [2]. Herein,
we report the first case of induced CTD in the form of
severe neuro-Sjögren’s syndrome in a patient treated
with pembrolizumab.
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Case presentation
A 69-year-old female patient diagnosed with acral lentigi-
nous melanoma of the left foot, pT3a pN2a cM0 R0, stage
IIIA, was treated by amputation of the first toe with
complete resection. Four years later, she developed histo-
logically confirmed multiple in-transit metastases requir-
ing recurrent excisions. The disease continued to
progress, with cutaneous and lymph node metastases. She
was enrolled in a clinical trial combining pembrolizumab
and T-VEC (talimogene laherparepvec, a GM-CSF-ex-
pressing oncolytic HSV-1 virus) administered by seven
intralesional injections [4]. The patient had no known
prior autoimmune disorders and had no neurologic mani-
festations prior to the CPI treatment.
Four months after the first dose of pembrolizumab,
the patient developed several vitiligo lesions, followed by
abnormal sensation with tingling and numbness of fin-
gers and hands suggestive of bilateral carpal tunnel syn-
drome 1 month later. Symptomatic treatment was
proposed, but neurological manifestation worsened pro-
gressively. At this time, the patient was considered in
complete remission and denied having any sicca syn-
drome, leading to the discontinuation of pembrolizumab
after having received eleven administrations.
Between eight and 10 months after the first dose of
pembrolizumab, she developed painful tingling sensations
in the hands and feet with pseudoathetoid (waver) move-
ments in the arms and hands and a progressive unsteady
gait. She was admitted to the hospital for worsening
neurologic symptoms and was first seen by the
neurologist.
On examination, she had a loss of sensation of the
right face, generalized absence of deep reflexes, and loss
of vibration and positional senses in the index and big
toes. Nerve conduction studies revealed the absence of
sensory nerve action potentials (SNAPs) in the upper
and lower limbs and reduced compound muscle action
potentials for the median and ulnar nerves but not for
the peroneal and tibial nerves. The brain MRI revealed
enhancement of the right trigeminal Gasser’s ganglia
and its mandibular branch (Fig. 1a and b). The cerebro-
spinal fluid (CSF) analysis showed a high level of protein
(1317 mg/l, normal: < 460) and pleocytosis (92 leuko-
cytes/μl, normal: < 5), with negative cultures, suggestive
of aseptic meningitis as CSF PCR testing was negative
for herpes-simplex types 1 and 2, varicella-zoster, cyto-
megalovirus, Epstein-Barr virus, HHV-6 and polyoma
JC-virus. Extensive work-up excluded infection with
HIV, Borrelia burgdorferi, syphilis and hepatitis viruses.
A diagnosis of sensory neuronopathy (SNN) was consid-
ered probable based on the pattern of her neuropathy
with a Camdessanche’s score of 11 (normal: < 6.5) [5].
Fig. 1 Brain MRI. Sagittal plane (a) and axial plane (b) showing enhancement of the trigeminal nerve (arrow) from the brainstem to the Gasser’s
ganglia (arrowhead). This enhancement disappeared during the treatment [sagittal plane, (c), and axial plane, (d)]
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The patient was at this time restricted to a wheelchair,
unable to stand and walk, and the overall neuropathy
limitations scale (ONLS) was 9 out of 12 (disability in
both arms preventing all function, requires wheelchair
to travel 10 m, but able to stand up and walk 1 m) [6].
The patient received intravenous pulses of methylpred-
nisolone (1 g/d) for 5 days and improved progressively
over 2 weeks, with an ONLS score passing from 9 to 5
(moderate disability in the upper limbs; walks with uni-
lateral aid for 10 m). She was discharged to a rehabilita-
tion center.
One month later, the patient was readmitted to the hos-
pital for severe ataxic relapse, with an ONLS score of 11,
and was restricted to her bed. Investigations were com-
pleted by an 18FDG-PET-CT that found no signs of mel-
anoma recurrence. Blood testing revealed an important
inflammatory syndrome with CRP levels at 18 mg/l (nor-
mal: < 10); erythrocyte sedimentation rate > 110 mm/h
(normal: < 20); hemolytic anemia hemoglobin at 98 g/l
(normal: 117 to 157), with haptoglobin at 0.1 g/l (normal:
0.3 to 2.0), LDH at 286 U/l (normal: 135 to 214), total bili-
rubin at 67 μmol/l (normal: 0 to 21), lymphopenia at
0.8 G/l, an elevation of the total IgG levels to 29.9 g/l,
(normal: 7.00 to 14.50) and presence of autoantibodies
such as antinuclear antibodies (ANAs): anti-SSA (52 kd at
48 CU, normal level: < 20, and 60 kd at 108 CU, normal
level: < 20). A panel of 45 antibodies involved in neuro-
logic paraneoplastic syndromes was negative, including
antineuronal (anti-HU and anti-Yo) and antiganglioside
antibodies (such as GQ1b). The following analyses were
negative or normal: antineutrophil cytoplasmic antibodies
(ANCAs): c-ANCA proteinase (PR3), p-ANCA myeloper-
oxidase (MPO) and atypical ANCA (x or a-ANCA);
rheumatoid factor; blood complement C3/C4; creatine
kinase; urine spot with proteinuria and creatininuria; crea-
tinemia and serum electrolytes. Of note, ANAs were nega-
tive in the serum sample that had been collected prior to
the initiation of pembrolizumab. A biopsy of the accessory
salivary glands (ASGB) showed abnormal interstitial scler-
osis with a focus of > 50 lymphocytes/4 mm2 (Chisholm
and Mason’s score of 3 out of 4) (Fig. 2). The findings
above led to a diagnosis of an induced Sjögren’s syndrome
(6 points according to the 2016 ACR/EULAR classifica-
tion criteria for Sjögren’s syndrome) [7] associated with
peripheral nervous system impairment.
After this relapse, an empirical “upfront” treatment
with pulses of intravenous methylprednisolone at 1 g/d
and immunoglobulins at 0.4 g/kg (both for 5 days) were
introduced in combination with acyclovir (which was
stopped after negative HSV PCR results in the CSF). In
the absence of clinical improvement, a second-line treat-
ment was initiated with cyclophosphamide at 15 mg/kg
(one dose) in association with oral prednisone at 60 mg/
d. Once the neuro-Sjögren diagnosis was established,
cyclophosphamide was replaced with rituximab adminis-
tered at 375 mg/m2 per dose once a month (for 4 ad-
ministrations at weeks 0, 2, 6 and 10). The decision to
change the therapy was made based on the similar
Fig. 2 Histopathological examination of a biopsy of the patient’s minor salivary gland. a and b Hematoxylin- and eosin-colored sections of minor
salivary gland biopsy specimens at 100x and 200x magnification, respectively, showing interstitial sclerosis with chronic interstitial inflammation and a
focus of ≥50 lymphocytes. c and d Immunohistochemical staining at 100x magnification with anti-CD3 and anti-CD20 antibody, respectively, with an
estimated CD3/CD20 ratio of 80/20
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efficacy of rituximab and cyclophosphamide for the
treatment of the neurologic manifestations of Sjögren’s
syndrome and to minimize the risk of T cell suppression
and melanoma recurrence.
The clinical improvement was then rapid, with a pro-
gressive amelioration of the ONLS score from 11 to 5.
The biological parameters improved in parallel, such as
normalization of the levels of hemoglobin, total biliru-
bin, IgG and erythrocyte sedimentation rate (Fig. 3). The
brain MRI showed a marked regression of the enhance-
ment of the trigeminal nerve (Fig. 1c and d).
After six monthly rituximab infusions, we observed
the total disappearance of B-cells in a second salivary
gland biopsy and normalization of the biological
markers, but the patient had persistent neurological defi-
cits, with the absence of deep reflexes, loss of sensation
in the distal part of the extremities, and imbalance when
walking with bilateral aid for 10 m.
Discussion and conclusions
Our patient developed subacute neurologic manifesta-
tions characterized by painful sensory sensations, pseu-
doathetoid movements in the arms and hands and a
progressive unsteady gait. Deep reflexes and SNAPs were
absent, fulfilling the diagnostic criteria of a sensory neu-
ronopathy [5]. SNNs are known for their frequent
association with dysimmune disorders including para-
neoplastic mechanisms [8]. In our case, the patient was
considered in complete remission of her melanoma
when sensory manifestations appeared, and repeated
work-ups did not suggest a paraneoplastic cause. Among
the other dysimmune SNNs, the most frequent associ-
ation is with Sjögren’s syndrome, accounting for 15–20%
of cases in the literature [9].
In our patient, the onset of the neurologic symptoms
began 12–14 weeks after CPI initiation, which was
slightly delayed compared to the typical neurologic irAEs
described in other studies [2], and she presented contin-
ued worsening despite the discontinuation of CPIs. This
time presentation and outcome are similar to what is ob-
served in complicated neuro-Sjögren’s syndrome and
typically require second-line treatment with cyclophos-
phamide or rituximab. Patients with inflammatory SNN
may benefit from immunomodulatory or immunosup-
pressive treatment if they are administered in a timely
manner, and it has been demonstrated that improvement
in the disease is possible if patients are treated within 2
months, hence the need for prompt referral to an expert
center [10].
Nerve conduction studies, particularly reduced SNAP
amplitude, are valuable markers for the diagnosis of
SNN [8]. The reduced amplitude of these potentials re-
flects the sensory neuronal degeneration and is an early
parameter for detecting the consequence of the inflam-
matory changes occurring in the dorsal root ganglia
(Gasser’s ganglia is the specific structure dedicated for
the face).
In our case, despite a total normalization of the in-
duced inflammation including biological and radiological
parameters, the neurological recovery remains partial.
One possible explanation is that the delayed treatment
of the induced ongoing dysimmune reaction caused irre-
versible neuronal loss.
Some inflammatory aspects of Sjögren’s syndrome are
well characterized, such as the lymphoplasmacytic cell
infiltration of the salivary glands [11]. A predominant
lymphocytic T-cell infiltration (approximately 80%) was
found in our patient, in opposition to the dysimmune
Fig. 3 Line graph showing the kinetic evolution of laboratory parameters of the patient including hemoglobin (g/l), total bilirubin (μmol/l), total
IgG (g/l) and erythrocyte sedimentation rate (mm/h) (x-axis showing time in months since the initiation of therapy)
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mechanisms implicated in the Sjögren’s-associated SNN
that have not been fully elicited. However, some
immuno-pathological features underlying several forms
of neuropathy have been reported by describing the de-
struction of sensory ganglion cells by lymphocytic infil-
tration [8]. In our case, except for the ASGB, we do not
have other biopsies and in particular no available neuro-
muscular tissues to assess this point. Other hypotheses
have also been mentioned, in particular that the pres-
ence of certain “unidentified” antigens primarily respon-
sible for Sjögren’s syndrome could be universally
“shared” among the target neural tissues.
Rash, pruritus and vitiligo are the most common skin
toxicities reported in CPI treatment, and they occurred
early in our patient. The occurrence of vitiligo in melanoma
patients receiving immunotherapy is associated with an im-
proved and durable anti-tumor response and better survival
[12]. Indeed, the patient has remained in complete remis-
sion despite the early discontinuation of immunotherapy.
Hematologic irAEs induced by CPIs are relatively uncom-
mon, but cases of autoimmune hemolytic anemia, throm-
botic thrombocytopenic purpura and autoimmune
thrombocytopenia have been reported [13–15]. In the case
of our patient, the origin of the hemolytic anemia could be
secondary to the Sjögren’s syndrome, although a direct at-
tribution to pembrolizumab cannot be excluded.
The frequency of CTD fully induced by CPI treatment re-
mains unknown. In contrast, a few reports have estimated
the incidence of CTD associated with CPI treatment to be
approximately 0.7% (3 out of 447 patients) [16]. However, all
three reported patients had pre-existing positive ANAs in
serum samples collected prior to CPI initiation, with two pa-
tients exhibiting pre-existing anti-SSA (despite the absence
of any clinical symptoms for a sicca syndrome or lupus),
which was not the case in the serum of our patient, who was
free from any type of autoantibodies (absence of ANA, SSA
52 and 60 kd) before CPI initiation. Therefore, we concluded
that it was not a decompensation of a pre-existing Sjögren’s
syndrome but presumably Sjögren’s syndrome induced by
pembrolizumab. To the best of our knowledge, this is the
first reported patient who developed Sjögren’s syndrome in-
duced by pembrolizumab treatment without demonstrated
pre-existing autoimmunity and complicated by severe neuro-
logical manifestations with a disabling sensory neuronopathy.
A possible synergetic implication of the concomitant T-VEC
injections in the irAEs cannot be formally excluded since this
oncolytic herpes virus encoding for GM-CSF may attract
dendritic cells to the injection site, which can process the
tumor antigens, leading to cytotoxic T cell antigen presenta-
tion that may stimulate an immune response. Indeed, it was
reported that 1% to 10% of TVEC-injected patients devel-
oped anemia and immune-mediated events (such as vascu-
litis, pneumonia, worsening psoriasis, glomerulonephritis
and vitiligo) [17].
This case study raises the question of the indications
for autoimmunity baseline screening in asymptomatic
patients prior to the initiation of CPIs, including a care-
ful medical history assessment and a baseline auto-
immunity laboratory evaluation, to individually assess
the autoimmunity risk. Patients with pre-existing disease
or asymptomatic autoimmune disorder are at risk of
worsening or developing the disease under CPI and
should therefore be closely monitored.
A retrospective study published by Menzies et al.
sought to explore the safety and efficacy of anti-PD-1
treatment in melanoma patients with pre-existing auto-
immune disorders (AIDs) and a history of irAEs during
ipilimumab treatment. Of the 119 patients included, 52
had a pre-existing autoimmune disorder, and 20 (38%)
had a flare of the autoimmune disorder requiring im-
munosuppression [18]. In case of suspected induced
AIDs, the assessment of the kinetics of respective auto-
antibody titers can be helpful for the diagnosis and may
aid in the early recognition and management of
treatment-related adverse events [19].
In conclusion, we have demonstrated here that a se-
vere disabling neuropathy could be associated with
neuro-Sjögren’s syndrome induced by pembrolizumab,
underlining the fact that a particular type of CTD can be
de novo induced in patients with no prior clinical or la-
boratory evidence of autoimmune disorders. Clinicians
are challenged to rapidly identify these complications
and promptly initiate immunosuppression or immuno-
modulatory treatment, which is essential to optimize
clinical outcome if administered in a timely manner. To
date, however, the optimal duration of immunosuppres-
sive treatment and the risks of late serious toxicities re-
main unknown.
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